FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140759353> ?p ?o ?g. }

• W2140759353 endingPage "68" @default.
• W2140759353 startingPage "59" @default.
• W2140759353 abstract "Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the mild AD subgroup (ITT data set: N = 118; MMSE: 21–25) are also presented. Methods: Patients with AD received 100 ml IV infusions of Cerebrolysin (10, 30 or 60 ml diluted in saline; N = 32, 34 and 35, respectively) or placebo (saline; N = 32) over twelve weeks (5 days per week for 4 weeks and 2 days per week for another 8 weeks). Primary efficacy criteria ADAS‐cog+ (Alzheimer’s Disease Assessment Scale Cognitive Subpart Modified) and CIBIC+ (Clinical Interview‐based Impression of Change with Caregiver Input) were assessed 24 weeks after baseline. Results: At week 24, Cerebrolysin improved the global clinical function significantly with all three dosages and induced significant improvements in cognition, initiation of activities of daily living (ADL) and neuropsychiatric symptoms at 10‐, 30‐ and 60‐ml doses, respectively. Treatment effects on total ADL and other secondary parameters (MMSE, Trail‐making test) were not significant. Cerebrolysin was safe and well tolerated. Conclusions: These results demonstrate the efficacy of Cerebrolysin in moderate to moderately severe AD, showing dose‐specific effects similar to those reported for patients with mild to moderate AD. The benefits of Cerebrolysin in advanced AD need to be confirmed in larger trials." @default.
• W2140759353 created "2016-06-24" @default.
• W2140759353 creator A5004538565 @default.
• W2140759353 creator A5021087962 @default.
• W2140759353 creator A5027441397 @default.
• W2140759353 creator A5027596710 @default.
• W2140759353 creator A5030041438 @default.
• W2140759353 creator A5033308925 @default.
• W2140759353 creator A5076708533 @default.
• W2140759353 creator A5084956700 @default.
• W2140759353 date "2010-12-15" @default.
• W2140759353 modified "2023-10-16" @default.
• W2140759353 title "Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin" @default.
• W2140759353 cites W1496490416 @default.
• W2140759353 cites W150154129 @default.
• W2140759353 cites W1555043404 @default.
• W2140759353 cites W1569923309 @default.
• W2140759353 cites W163864813 @default.
• W2140759353 cites W1847168837 @default.
• W2140759353 cites W1953027527 @default.
• W2140759353 cites W1979675033 @default.
• W2140759353 cites W2007121025 @default.
• W2140759353 cites W2009646399 @default.
• W2140759353 cites W2018780010 @default.
• W2140759353 cites W2023363182 @default.
• W2140759353 cites W2024719735 @default.
• W2140759353 cites W2042920190 @default.
• W2140759353 cites W2046917916 @default.
• W2140759353 cites W2057679568 @default.
• W2140759353 cites W2061378977 @default.
• W2140759353 cites W2067029852 @default.
• W2140759353 cites W2068926471 @default.
• W2140759353 cites W2072249708 @default.
• W2140759353 cites W2084973227 @default.
• W2140759353 cites W2102343148 @default.
• W2140759353 cites W2111963393 @default.
• W2140759353 cites W2115574704 @default.
• W2140759353 cites W2119062449 @default.
• W2140759353 cites W2125078674 @default.
• W2140759353 cites W2137103253 @default.
• W2140759353 cites W2140665706 @default.
• W2140759353 cites W2140719894 @default.
• W2140759353 cites W2160310540 @default.
• W2140759353 cites W2321934698 @default.
• W2140759353 cites W4254526107 @default.
• W2140759353 cites W55494773 @default.
• W2140759353 doi "https://doi.org/10.1111/j.1468-1331.2010.03092.x" @default.
• W2140759353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20500802" @default.
• W2140759353 hasPublicationYear "2010" @default.
• W2140759353 type Work @default.
• W2140759353 sameAs 2140759353 @default.
• W2140759353 citedByCount "57" @default.
• W2140759353 countsByYear W21407593532012 @default.
• W2140759353 countsByYear W21407593532013 @default.
• W2140759353 countsByYear W21407593532014 @default.
• W2140759353 countsByYear W21407593532015 @default.
• W2140759353 countsByYear W21407593532016 @default.
• W2140759353 countsByYear W21407593532017 @default.
• W2140759353 countsByYear W21407593532018 @default.
• W2140759353 countsByYear W21407593532019 @default.
• W2140759353 countsByYear W21407593532020 @default.
• W2140759353 countsByYear W21407593532021 @default.
• W2140759353 countsByYear W21407593532022 @default.
• W2140759353 countsByYear W21407593532023 @default.
• W2140759353 crossrefType "journal-article" @default.
• W2140759353 hasAuthorship W2140759353A5004538565 @default.
• W2140759353 hasAuthorship W2140759353A5021087962 @default.
• W2140759353 hasAuthorship W2140759353A5027441397 @default.
• W2140759353 hasAuthorship W2140759353A5027596710 @default.
• W2140759353 hasAuthorship W2140759353A5030041438 @default.
• W2140759353 hasAuthorship W2140759353A5033308925 @default.
• W2140759353 hasAuthorship W2140759353A5076708533 @default.
• W2140759353 hasAuthorship W2140759353A5084956700 @default.
• W2140759353 hasConcept C126322002 @default.
• W2140759353 hasConcept C142724271 @default.
• W2140759353 hasConcept C162156334 @default.
• W2140759353 hasConcept C168563851 @default.
• W2140759353 hasConcept C204787440 @default.
• W2140759353 hasConcept C27081682 @default.
• W2140759353 hasConcept C2776149669 @default.
• W2140759353 hasConcept C2779134260 @default.
• W2140759353 hasConcept C42219234 @default.
• W2140759353 hasConcept C502032728 @default.
• W2140759353 hasConcept C535046627 @default.
• W2140759353 hasConcept C71924100 @default.
• W2140759353 hasConceptScore W2140759353C126322002 @default.
• W2140759353 hasConceptScore W2140759353C142724271 @default.
• W2140759353 hasConceptScore W2140759353C162156334 @default.
• W2140759353 hasConceptScore W2140759353C168563851 @default.
• W2140759353 hasConceptScore W2140759353C204787440 @default.
• W2140759353 hasConceptScore W2140759353C27081682 @default.
• W2140759353 hasConceptScore W2140759353C2776149669 @default.
• W2140759353 hasConceptScore W2140759353C2779134260 @default.
• W2140759353 hasConceptScore W2140759353C42219234 @default.
• W2140759353 hasConceptScore W2140759353C502032728 @default.
• W2140759353 hasConceptScore W2140759353C535046627 @default.
• W2140759353 hasConceptScore W2140759353C71924100 @default.
• W2140759353 hasIssue "1" @default.

• next